Skip to main content
UniHealth

Doctor search

Eric Kam-Chuan Lau, DO

Hematology/Oncology · Palo Alto

NPI 1891182465

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
2
2 carriers
Offices
6

Offices

6 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group

Looking this up.

Hospitals listed: Mills-Peninsula Medical Center · Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

2 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lau’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

2 of 2 plans

Plans whose provider directory lists this clinician
Alignment Health Sutter Advantage +More (HMO)Alignment Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Peninsula Medical Center

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Peninsula Medical Center
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.139BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.242BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.21 (0.27 to 2.15) · 1,258 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.81 (0.51 to 1.1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths155.44 (112.67 to 198.21) · 90 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.5 · 32 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.1 · 82 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10 · 188 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9 · 473 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths14.8 · 342 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.4 · 485 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.9 · 3,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.2 (0 to 0.4) · 6,904 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.21 (0.02 to 0.4) · 7,052 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.41 (1.43 to 5.39) · 1,695 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.72 (0.17 to 3.28) · 665 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.11 (0.66 to 3.56) · 1,545 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.1 (1.3 to 12.9) · 670 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.96 (2.63 to 9.29) · 653 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.15 to 3.08) · 418 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.14 (0 to 0.78) · 5,539 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.7 · 192 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.215No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.263No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.74No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits14.3 · 300 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits19 · 702 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits1.2 · 207 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-13.6 · 531 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits24.3 · 343 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits18.1 · 449 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits4.5 (2.8 to 7) · 85 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits9.6 (6.7 to 13.7) · 85 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.7 · 189 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits11 · 45 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20.6 · 117 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13 (9.7 to 17.2) · 584 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.9 (0.7 to 1.2) · 764 casesNo differentJan 2024 – Dec 2024

What patients said (523 patients answered, 27% of those asked)

Patient survey stars by topic at Peninsula Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness3
Recommend hospital5
Share of patients giving the best answer at Peninsula Medical Center
Room was "always" clean76%
Nurses "always" communicated well81%
Doctors "always" communicated well80%
Staff "always" explained58%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully79%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)75%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night54%
"YES", patients would definitely recommend the hospital78%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$2,750,052

Medicare paid this office $2,750,052 for 601 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Injection, pembrolizumab, 1 mg18$499,947None
Injection, daratumumab, 10 mg and hyaluronidase-fihj12$412,579None
Injection, vedolizumab, intravenous, 1 mg12$104,294None
Long return visit (40+ min)149$61,036$168
Injection, eptinezumab-jjmr, 1 mg12$60,581None
See all 38 services
Every Original Medicare service billed
Injection, pembrolizumab, 1 mg18$499,947None
Injection, daratumumab, 10 mg and hyaluronidase-fihj12$412,579None
Injection, vedolizumab, intravenous, 1 mg12$104,294None
Long return visit (40+ min)149$61,036$168
Injection, eptinezumab-jjmr, 1 mg12$60,581None
Administration of chemotherapy into vein, 1 hour or less97$33,180$141
Injection, golimumab, 1 mg, for intravenous use11$26,506None
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less185$19,749$67
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or109$17,040$29
Return visit (30+ min)66$12,453$120
New patient visit (60+ min)46$9,002$196
Short return visit (20+ min)85$8,786$85
Leuprolide acetate (for depot suspension), 7.5 mg13$8,063None
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle15$5,808$77
Administration of additional new drug or substance into vein, 1 hour or less28$4,452$68
New patient visit (30+ min)38$3,627$95
New patient visit (45+ min)23$3,625$158
Bcg live intravesical instillation, 1 mg16$3,452None
Injection, zoledronic acid, 1 mg143$3,436None
Injection of drug or substance into vein73$3,186$39
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour27$3,035$21
Injection of additional new drug or substance into vein62$3,001$16
Instillation of anti-cancer drug into bladder16$2,668$89
Administration of chemotherapy into vein, each additional hour35$2,557$29
Administration of additional new drug or substance into vein using push technique17$2,280$58
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less29$1,731$30
Short return visit26$1,564$54
Office for the evaluation and management of established patient that may not require presence of healthcare professional37$1,076$23
Injection of drug or substance under skin or into muscle34$860$14
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle16$824$37
New patient visit (15+ min)11$780$71
Injection, fosaprepitant, 1 mg24$673None
Infusion into a vein for hydration, each additional hour20$627$13
Injection, ondansetron hydrochloride, per 1 mg40$83None
Infusion, normal saline solution, 250 cc116$82None
Injection, dexamethasone sodium phosphate, 1 mg41$81None
Injection, diphenhydramine hcl, up to 50 mg28$38None
Unclassified drugs11$10None

Who their Medicare patients are

601 Original Medicare patients in 2024. Average age 77 · Under 65 3% · 85 and older 18% · Women 63% · Also on Medicaid 4% · Health risk score 1.32. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.

Conditions among them: High blood pressure 60% · Cancer 32% · Coronary heart disease 24% · Chronic kidney disease 22% · Diabetes 16% · Atrial fibrillation 16% · Depression 13% · Heart failure 12% · COPD 9% · Dementia 6% · Stroke 5%.

The office billed $8,716,316, Medicare allowed $3,448,880 and paid $2,750,052; for 125,754 services of 136 kinds; $2,534,997 of it was for drugs given in the office and $215,055 for care.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024601125,754771.32$8,716,316$2,750,052
20231076,274761.55$500,255$170,594
20191820636.10$12,650$3,471
20181717663.68$10,474$2,885

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 4 services

Original Medicare services billed in 2023
Long return visit (40+ min)43$9,662$170
New patient visit (60+ min)24$4,785$199
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or33$4,214$29
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less11$756$69

2019: 1 service

Original Medicare services billed in 2019
Initial hospital care with moderate level of medical decision making at least 75 minutes17$3,256$181

2018: 1 service

Original Medicare services billed in 2018
Initial hospital care with moderate level of medical decision making at least 75 minutes14$2,547$182

Drugs they prescribed that Part D paid

$1,996,547

Pharmacies billed $1,996,547 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 4% of their Part D prescriptions (31 of 722) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.

503 generic and 219 brand-name prescriptions · $1,996,547 in drug cost · 36 antibiotic prescriptions to 16 people · 34 antipsychotic prescriptions to people over 65.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Revlimid15$280,680$18,712
Pomalyst11$273,120$24,829
Venclexta16$244,864$15,304
Alecensa11$186,010$16,910
Nubeqa11$149,767$13,615
See all 18 drugs
Every Part D drug this clinician prescribed
Revlimid15$280,680$18,712
Pomalyst11$273,120$24,829
Venclexta16$244,864$15,304
Alecensa11$186,010$16,910
Nubeqa11$149,767$13,615
Eliquis60$53,166$886
Abiraterone Acetate16$12,441$778
Olanzapine34$874$26
Acyclovir51$481$9
Dexamethasone24$422$18
Anastrozole21$365$17
Ondansetron Odt17$351$21
Prochlorperazine Maleate34$315$9
Sulfamethoxazole-Trimethoprim22$166$8
Gabapentin11$90$8
Lorazepam20$85$4
Prednisone18$77$4
Ondansetron15$70$5

Year by year

Part D prescribing by year
20247221184% (31)30%$1,996,547
202322048None17%$199,237
202215439None8%$219,163
2021187317% (13)11%$275,611
202011020None15%$85,763
20192713NoneNone$2,578

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 3 drugs

Part D drugs prescribed in 2023
Eliquis11$9,960$905
Acyclovir30$674$22
Sulfamethoxazole-Trimethoprim29$430$15

2022: 3 drugs

Part D drugs prescribed in 2022
Acyclovir11$392$36
Dexamethasone12$279$23
Sulfamethoxazole-Trimethoprim13$121$9

2021: 4 drugs

Part D drugs prescribed in 2021
Anastrozole19$407$21
Dexamethasone20$324$16
Ondansetron14$185$13
Prochlorperazine Maleate13$149$11

2020: 1 drug

Part D drugs prescribed in 2020
Anastrozole12$196$16

Money from drug and device companies

$301 in 2025

Industry payments by year
202548None$301
202411None$162
202311None$105
202211None$25
202125None$500
202022None$116
201922None$170

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Daiichi SankyoDatroway$162
3 payments
  • Meals for Datroway · 2025-11-21 · $22
  • Meals for Datroway · 2025-10-08 · $135
  • Meals for Enhertu · 2025-01-28 · $5
AstraZeneca Pharmaceuticals LPCalquence$76
3 payments
  • Meals for Calquence · 2025-07-17 · $20
  • Meals for Enhertu · 2025-05-14 · $26
  • Meals for Calquence · 2025-02-24 · $30
Janssen BiotechTremfya$35
1 payment
  • Meals for Tremfya · 2025-06-29 · $35
Caris MPIMi Cancer Seek$27
1 payment
  • Meals for Mi Cancer Seek · 2025-08-25 · $27
See all 8 published payments
Every published payment
Daiichi SankyoMeals · 2025-11-21Datroway$22
Daiichi SankyoMeals · 2025-10-08Datroway$135
Caris MPIMeals · 2025-08-25Mi Cancer Seek$27
AstraZeneca Pharmaceuticals LPMeals · 2025-07-17Calquence$20
Janssen BiotechMeals · 2025-06-29Tremfya$35
AstraZeneca Pharmaceuticals LPMeals · 2025-05-14Enhertu$26
AstraZeneca Pharmaceuticals LPMeals · 2025-02-24Calquence$30
Daiichi SankyoMeals · 2025-01-28Enhertu$5
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $162

Payments by company in 2024
AstraZeneca Pharmaceuticals LPEnhertu$162
1 payment
  • Meals for Enhertu · 2024-08-13 · $162

2023: $105

Payments by company in 2023
GenzymeEnjaymo$105
1 payment
  • Meals for Enjaymo · 2023-12-08 · $105

2022: $25

Payments by company in 2022
AstraZeneca Pharmaceuticals LPLynparza$25
1 payment
  • Meals for Lynparza · 2022-05-07 · $25

2021: $500

Payments by company in 2021
Takeda Pharmaceuticals U.S.A.Iclusig$325
3 payments
  • Meals for Iclusig · 2021-10-28 · $125
  • Education · 2021-06-21 · $100
  • Education · 2021-06-21 · $100
Janssen BiotechImbruvica$175
2 payments
  • Education for Imbruvica · 2021-07-12 · $90
  • Education for Imbruvica · 2021-01-07 · $85

2020: $116

Payments by company in 2020
SeagenNone$95
1 payment
  • Education · 2020-02-05 · $95
AmgenNone$21
1 payment
  • Meals · 2020-02-24 · $21

2019: $170

Payments by company in 2019
Takeda Pharmaceuticals U.S.A.Velcade$111
1 payment
  • Education for Velcade · 2019-08-28 · $111
Stemline TherapeuticsElzonris$60
1 payment
  • Meals for Elzonris · 2019-08-24 · $60

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
84.9 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1891182465
Licence
CA 20A15311
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207RH0003X (207RH0003X)
Mailing address
325 Distel Cir, Los Altos, CA, 94022
NPI first listed
2015-04-22
NPI last updated
2023-09-29
NPI record certified
2023-09-29

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305